Evidence map›Paper›PMID 28405067›Full record

ReviewProceedings (Baylor University. Medical Center)2017

Heterogeneity of systematic reviews in oncology.

Jonathan Holmes, David Herrmann, Chelsea Koller, Sarah Khan, Blake Umberham, Jody A Worley, Matt Vassar

Abstract readReview
In one paragraph

Review in Proceedings (Baylor University. Medical Center), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jonathan HolmesOklahoma State University Center for Health Sciences, Tulsa, Oklahoma (Holmes, Herrmann, Koller, Khan, Umberham, Vassar) and the University of Oklahoma, Norman, Oklahoma (Worley).
David HerrmannOklahoma State University Center for Health Sciences, Tulsa, Oklahoma (Holmes, Herrmann, Koller, Khan, Umberham, Vassar) and the University of Oklahoma, Norman, Oklahoma (Worley).
Chelsea KollerOklahoma State University Center for Health Sciences, Tulsa, Oklahoma (Holmes, Herrmann, Koller, Khan, Umberham, Vassar) and the University of Oklahoma, Norman, Oklahoma (Worley).
Sarah KhanOklahoma State University Center for Health Sciences, Tulsa, Oklahoma (Holmes, Herrmann, Koller, Khan, Umberham, Vassar) and the University of Oklahoma, Norman, Oklahoma (Worley).
Blake UmberhamOklahoma State University Center for Health Sciences, Tulsa, Oklahoma (Holmes, Herrmann, Koller, Khan, Umberham, Vassar) and the University of Oklahoma, Norman, Oklahoma (Worley).
Jody A WorleyOklahoma State University Center for Health Sciences, Tulsa, Oklahoma (Holmes, Herrmann, Koller, Khan, Umberham, Vassar) and the University of Oklahoma, Norman, Oklahoma (Worley).
Matt VassarOklahoma State University Center for Health Sciences, Tulsa, Oklahoma (Holmes, Herrmann, Koller, Khan, Umberham, Vassar) and the University of Oklahoma, Norman, Oklahoma (Worley).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systematic reviews synthesize data across multiple studies to answer a research question, and an important component of the review process is to evaluate the heterogeneity of primary studies considered for inclusion. Little is known, however, about the ways that systematic reviewers evaluate heterogeneity, especially in clinical specialties like oncology. We examined a sample of systematic reviews from this body of literature to determine how meta-analysts assessed and reported heterogeneity. A PubMed search of 6 oncology journals was conducted to locate systematic reviews and meta-analyses. Two coders then independently evaluated the manuscripts for 10 different elements based on an abstraction manual. The initial PubMed search yielded 337 systematic reviews from 6 journals. Screening for exclusion criteria (nonsystematic reviews, genetic studies, individual patient data, etc.) found 155 articles that did not meet the definition of a systematic review. This left a final sample of 182 systematic reviews across 4 journals. Of these reviews, 50% (91/182) used varying combinations of heterogeneity tests, and of those, 16% (15/91) of review authors noted excessive heterogeneity and opted to not perform a meta-analysis. Of the studies that measured heterogeneity, 51% (46/91) used a random-effects model, 7% (8/91) used a fixed-effects model, and 43% (39/91) used both. We conclude that use of quantitative and qualitative heterogeneity measurement tools are underused in the 4 oncology journals evaluated. Such assessments should be routinely applied in meta-analyses.

Identifiers

PMID28405067
PMCPMC5349813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.